Concomitant Chemoradiotherapy Demonstrates Survival Benefit in Nasopharyngeal CarcinomaMarch 16th 2017
The addition of chemotherapy, either adjuvant or induction, to concomitant chemoradiotherapy (CRT) achieved a significantly high survival benefit for patients with locally advanced nasopharyngeal carcinoma.
Rovalpituzumab Tesirine Demonstrates Encouraging Activity in Small Cell Lung CancerFebruary 14th 2017
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, demonstrated encouraging single-agent antitumor activity with a manageable safety profile in the treatment of patients with recurrent small cell lung cancer.
Study Finds Weight Loss Associated With Lower Endometrial Cancer RiskFebruary 13th 2017
Intentional weight loss in postmenopausal women is associated with a lower endometrial cancer risk, particularly among those with obesity, according to the results of a recent study published in the <em>Journal of Clinical Oncology</em>.<br />
New Marker Could Help Detect Need for More Aggressive Prostate Cancer TreatmentJanuary 27th 2017
A prostate-specific antigen nadir greater than 0.5 ng/mL following radiation and androgen deprivation therapy seems to identify men prior to PSA failure who are at high-risk for death, and would thus require more aggressive treatment for their prostate cancer.
Sharp Decline Seen in Prostate Cancer Treatment RatesJanuary 27th 2017
Tudor Borza, MD, discusses the major findings of his study that found a sharp decline in the overall rate of men receiving treatment for prostate cancer and his stance on the importance of prostate cancer screening and treatment.
An Overview of the Updated HPV Vaccine RecommendationsJanuary 26th 2017
The University of Texas MD Anderson Cancer Center has united with the 68 other National Cancer Institute–designated cancer centers in issuing a joint statement that endorses the recently revised vaccination recommendations from the CDC.
Osimertinib Greatly Reduces Disease Progression Risk in EGFR T790M-Mutant NSCLCDecember 8th 2016
Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed after first-line targeted therapy, according to phase III clinical trial results.
Radiomics Could Play Important Predictive Role in Patient Outcomes in SarcomaNovember 12th 2016
Though surgical resection and radiation therapy remain at the forefront of the treatment for localized disease, accurately predicting outcomes for individual patients remains a challenge, which radiomics, an emerging research field, hopes to alleviate.
Expert Highlights Factors Influencing Local Control in Ewing SarcomaNovember 11th 2016
<br /> Local recurrence is associated with very poor prognosis in patients with Ewing sarcoma. Researchers are seeking to identify the factors associated with local recurrence in patients undergoing multimodal treatment.
Though Much on the Horizon in HER2+ Breast Cancer Treatment, There Is Still Work to Be DoneNovember 8th 2016
Though some clinicians may characterize the treatment landscape of HER2-positive breast cancer as overcrowded, Mark Pegram, MD, firmly believes that there is still much to learn in this space.